Drug Type Fusion protein |
Synonyms AB 004, AB004 |
Action modulators |
Mechanism APRIL modulators(Tumor necrosis factor ligand superfamily member 13 modulators), BAFF modulators(B-cell-activating factor/B lymphocyte stimulator modulators), IL-11 modulators(interleukin 11 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Chronic Kidney Diseases | Preclinical | United States | 01 Dec 2024 | |
| Nonalcoholic Steatohepatitis | Preclinical | United States | 01 Dec 2024 | |
| Fibrosis, Liver | Preclinical | United States | 18 Jun 2024 | |
| Renal fibrosis | Preclinical | United States | 18 Jun 2024 | |
| Idiopathic Pulmonary Fibrosis | Discovery | United States | 10 Feb 2022 |






